Drugs Not ‘On Radar’ For Medicare Coverage Review, Official Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The director of Medicare’s coverage and analysis group says that, at the moment, no biopharma products are being considered for a national coverage determination. Another official says Medicare cannot use comparative effectiveness data in making reimbursement decisions.
You may also be interested in...
Paying For Placebo Is ‘Biggest Change’ In Medicare CED Policy, Official Says
The director of Medicare’s coverage group sees the ability to pay physicians for providing a placebo in clinical trials required under a ‘coverage with evidence development’ determination as a major improvement in its recent guidance for CED.
Medicare Will Cover Provenge Labeled Uses, CMS Proposes; Off-Label Is Up To Contractors
Agency decides against requiring coverage with evidence development for off-label uses.
Medicare Part B Drug "Least Costly Alternative" Policy Rescinded By CMS
Policy had been used to limit expenditures for prostate cancer drugs and inhaled drugs for pulmonary disease.